NewAmsterdam Pharma Secures $707.3M Cash, Eyes 2H26 Approvals and 4Q26 Launches
NAMS•NewAmsterdam Pharma ended Q1 with $707.3 million in cash and equivalents as of March 31, 2026 and expects 2H26 regulatory decisions on obicetrapib-ezetimibe combo with potential Menarini launches in Germany and the UK in 4Q26. Enrollment in REMBRANDT completed and RUBENS topline data are expected by year-end 2026.
1. Q1 Financial Results and Cash Position
NewAmsterdam Pharma reported $707.3 million in cash, cash equivalents and marketable securities as of March 31, 2026, bolstering its balance sheet to fund late-stage clinical trials and corporate operations.
2. Regulatory and Commercial Milestones
Decisions from EMA, UK and Swiss regulators on obicetrapib and the obicetrapib-ezetimibe fixed-dose combination are expected in the second half of 2026, with potential launches by partner Menarini in Germany and the UK in the fourth quarter.
3. Pipeline Progress and Clinical Trials
The REMBRANDT Phase 3 trial has completed enrollment, RUBENS topline data are anticipated by year-end 2026, and PREVAIL’s interim analysis is scheduled for 4Q26 with results in 1Q27. Recent pooled analyses from BROOKLYN and BROADWAY demonstrated sustained LDL-C reductions, slower annual eGFR decline and a solid safety profile.
